New acridine-9-carboxamide linked to 1,2,3-triazole-N-phenylacetamide derivatives as potent α-glucosidase inhibitors: design, synthesis, in vitro, and in silico biological evaluations

doi:10.1007/s00044-020-02603-7

Paper

New acridine-9-carboxamide linked to 1,2,3-triazole-N-phenylacetamide derivatives as potent α-glucosidase inhibitors: design, synthesis, in vitro, and in silico biological evaluations

Published Jul 22, 2020 · Nima Sepehri, Nafise Asemanipoor, Seyed Ali Mousavianfard

Medicinal Chemistry Research

Q2 SJR score

15

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

α-Glucosidase plays a major role in degradation of carbohydrates to glucose. Therefore, inhibition of this enzyme can be useful in the treatment of carbohydrate-related diseases such as diabetes, cancer, and viral infections. In this study, a new series of acridine-9-carboxamide linked to 1,2,3-triazole-N-phenylacetamide derivatives 5a–m were designed, synthesized, and evaluated as potent α-glucosidase inhibitors. All the synthesized compounds showed excellent to good inhibitory activity against α-glucosidase with IC50 values of 80.3 ± 0.9–564.3 ± 7.2 µM in comparison with standard drug acarbose (IC50 value = 750.0 ± 10.5 μM). Among the synthesized compounds, the most active compound was 3-bromo derivative 5h with inhibitory activity around 9.3 times more than acarbose. this compound was selected for farther biological evaluations. Kinetic study of compound 5h revealed that it is a competitive inhibitor against α-glucosidase. Docking study of compound 5h and its regioisomer 5i with 4-bromo substituent were also carried out in the active site of α-glucosidase to gain an insight into the interaction modes of the synthesized compounds and rationalized structure–activity relationship between these two compounds. Compound 5h was also evaluated against α-amylase and no activity was observed in comparison with acarbose. Furthermore, in vitro cytotoxic assay of compound 5h against human normal and cancer cell lines HDF and MCF-7, respectively, revealed that this compound is a noncytotoxic agent. In silico pharmacokinetic and toxicity assays of compound 5h was performed and obtained results were compared with acarbose.

In Vitro Study

Study Snapshot

The 3-bromo derivative 5h shows 9.3 times more inhibitory activity than acarbose, making it a promising compound for treating carbohydrate-related diseases like diabetes, cancer, and viral infections.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

New acridine-9-carboxamide linked to 1,2,3-triazole-N-phenylacetamide derivatives as potent α-glucosidase inhibitors: design, synthesis, in vitro, and in silico biological evaluations

Sign up to use Study Snapshot

References

Synthesis of sulpha drug based hydroxytriazene derivatives: Anti-diabetic, antioxidant, anti-inflammatory activity and their molecular docking studies.

Sulfa drug-based hydroxytriazenes show potential as antidiabetic, anti-inflammatory, and antioxidant candidates, with experimental validation of their activities.

Synthesis and biological evaluation of new benzimidazole-1,2,3-triazole hybrids as potential α-glucosidase inhibitors.

New benzimidazole-1,2,3-triazole hybrids show promising potential as new -glucosidase inhibitors, with more inhibitory activity than standard drug acarbose.

Synthesis and molecular docking studies of imines as α-glucosidase and α-amylase inhibitors.

This study presents an eco-friendly, straightforward synthesis pathway for aryl imines, which show inhibitory activity against -glucosidase and -amylase enzymes, with potential applications in pharmaceuticals and biotechnology.

Biscoumarin-1,2,3-triazole hybrids as novel anti-diabetic agents: Design, synthesis, in vitro α-glucosidase inhibition, kinetic, and docking studies.

Biscoumarin-1,2,3-triazole hybrids show excellent -glucosidase inhibitory activity, with compounds 6c and 6g showing the highest inhibitory activity and being non-cytotoxic towards normal fibroblast cells.

Synthesis, in vitro alpha-glucosidase inhibitory potential of benzimidazole bearing bis-Schiff bases and their molecular docking study.

Benzimidazole bearing bis-Schiff bases show excellent to good alpha-glucosidase inhibitory potential, potentially offering a safer alternative to standard drugs like acarbose for diabetes management.

Citations

1,2,3-Triazole based xanthene and acridine linkers as potential α-glucosidase and α-amylase inhibitors: design, green synthesis, kinetics, and in silico studies

The synthesis of xanthene and acridine linked 1,2,3-triazole derivatives using ultrasound-promoted deep eutectic solvent resulted in efficient and environmentally friendly production of promising -glucosidase and -amylase inhibitors for type

TBAI‐TBHP Mediated C4‐Selective C(sp3)‐H Sulfonylation of 1,2,3,4‐Tetrahydroacridines and Oxidative Desulfonylation to 2,3‐Dihydro Acridin‐4(1H)‐Ones

This study demonstrates a metal-free, site-selective C(sp3)-H sulfonylation of 1,2,3,4-tetrahydroacridines and its extension to 2,3-dihydroacridin-4(1H)-ones in good to

The anti‐breast cancer therapeutic potential of 1,2,3‐triazole‐containing hybrids

1,2,3-triazole-containing hybrids show promising anti-breast cancer potential against both drug-sensitive and drug-resistant forms, offering privileged scaffolds for the discovery of novel anti-breast cancer candidates.

A Combined Experimental and Computational Study of Novel Benzotriazinone Carboxamides as Alpha-Glucosidase Inhibitors

Novel benzotriazinone carboxamides 14k and 14l show strong alpha-glucosidase inhibition potential, offering a potential new antidiabetic drug with reduced side effects.

Synthetic α-glucosidase inhibitors as promising anti-diabetic agents: Recent developments and future challenges.

Synthetic -glucosidase inhibitors based on aromatic heterocyclic scaffolds show promising anti-diabetic properties with reduced side effects and cost.